- Generic name
- Palonosetron
- Strength
- .25 mg/vial
- Dosage form
- Injection
- Manufactured by
- Renata PLC.
Vomiren-0.25 Injection
About Vomiren-0.25 Injection
Vomiren-0.25 is an injection made by Renata PLC. It contains the anti-emetic medicine palonosetron and is supplied as a 0.25 mg vial.
There are 16 brands of Palonosetron listed in Bangladesh.
What is Vomiren-0.25 Injection?
Vomiren-0.25 is a prescription injection from Renata PLC. Its active ingredient is palonosetron, which belongs to a group of medicines called anti-emetics. It works by blocking a receptor involved in the vomiting reflex. It is used in situations such as nausea and vomiting after chemotherapy or radiotherapy, and in some cases of uncontrolled or postoperative nausea and vomiting. It is given by a healthcare professional as an injection. The dose, timing and course are set by the doctor, and the injection should not be used without medical supervision.
Uses of Vomiren-0.25
Vomiren-0.25 is used to help manage nausea and vomiting. These include acute and delayed nausea and vomiting, uncontrolled nausea and vomiting, and nausea and vomiting linked to chemotherapy or radiotherapy. It may also be used for nausea and vomiting after surgery. It is an anti-emetic, a medicine that acts against vomiting. Only a doctor can decide whether this injection is suitable for a particular patient.
How to use Vomiren-0.25
Vomiren-0.25 is an injection, so it is given by a doctor or other trained healthcare professional. Patients should not inject it themselves. The dose, the timing in relation to chemotherapy, radiotherapy or surgery, and the length of the course are all decided by the doctor. Ask your doctor or pharmacist about anything you are unsure of, including how the injection will be given and what to expect afterwards.
Side effects of Vomiren-0.25
The most common side effects reported with palonosetron are headache and constipation. Not everyone who receives the injection will have these effects. Tell your doctor or nurse if you notice any side effect after the injection, or if you have any concerns about how you feel. Your healthcare team can advise on what to do and whether any further care is needed. Ask the doctor about any other possible effects.
Safety and precautions
Vomiren-0.25 should not be given to anyone known to be allergic to palonosetron or to any of the ingredients in the injection. It belongs to pregnancy category B; if you are pregnant, think you may be pregnant, or are breastfeeding, tell your doctor before it is given, because it is not known whether palonosetron passes into breast milk. Tell your doctor about all other medicines you take and about any health conditions you have. Only the doctor can decide whether this injection is appropriate for you.
Frequently asked questions
How is Vomiren-0.25 taken?
It is an injection, not a tablet, so it is given by a doctor or another trained healthcare professional. The dose, the timing and how long the course lasts are decided by the doctor. Do not try to use it yourself. Ask your doctor or pharmacist if you have questions about how it will be given.
What is Vomiren-0.25 used for and what kind of medicine is it?
It is an anti-emetic medicine, which means it is used to help manage nausea and vomiting. These include nausea and vomiting linked to chemotherapy or radiotherapy, uncontrolled nausea and vomiting, and nausea and vomiting after surgery. The doctor decides whether it is suitable for you.
What does the dosage form and strength mean?
The dosage form is an injection, so the medicine is given by a trained healthcare professional rather than swallowed. The strength is 0.25 mg per vial, which describes how much palonosetron the vial contains. The doctor decides how much of the vial is used and when it is given.
Who should ask a doctor before receiving Vomiren-0.25?
Anyone with a known allergy to palonosetron or to any ingredient should tell the doctor. Pregnant women, women who are breastfeeding, and people taking other medicines should also speak to the doctor first. The doctor will decide whether this injection is appropriate for you.
Indications
- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
- Delayed CINV resulting in on days later with certain types of chemotherapy ... Read more
- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
- Delayed CINV resulting in on days later with certain types of chemotherapy
- Radiotherapy-induced nausea and vomiting (RINV)
- Post-operative & Post-discharge nausea and vomiting (PONV & PDNV).
Pharmacology
Pharmacokinetics: Palonosetron exhibits linear dose-proportional pharmacokinetics over the doserange 1-90 pg/kg in healthy subjects and in patients with cancer. In cancer patients receiving single intravenous doses of Palonosetron in this dose range, the mean maximum plasma concentration (Cmax) ranges from 0.89 to 336 ng/ml and the area under the plasma concentration-time curve from zero to infinity (AUCo-co) ranges from 13.8 to 957 ng.h/ml. Palonosetron has a volume of distribution of approximately 6.9-7.9 L/kg, with approximately 62% bound to plasma proteins. Approximately 50% of Palonosetron is metabolized into two inactive metabolites that exhibit <1% of the 5-HT3 receptor antagonist activity. Approximately 40% of the drug is metabolised via kidney, 50% by liver CYP2D6 (mainly), CYP3A4 and CYP1A2 isoenzymes. About 50% of the drug goes under metabolism. After a single intravenous dose, approximately 40% is excreted as unchanged drug in the urine after 144 hours. Total body clearance of Palonosetron is 160±35 ml/h/kg, and renal clearance is 66.5±18.2 ml/h/kg in healthy subjects. Palonosetron exhibits a longer half-life (40 hours) and has a greater 5-HT3 receptor binding affinity.
Dosage & Administration
Chemotherapy-induced nausea and vomiting: Adult tablet dosage: 0.5 mg administered approximately 1 hour prior to the start of chemotherapy. Adult IV dosage: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before the start of chemotherapy.
Radiotherapy-induced nausea and vomiting: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before each week of radiation fraction.
Post-operative nausea and vomiting: A single IV dose of 0.075 mg should be administered over 10 seconds immediately before induction of anesthesia.
Children dosage: (1 month to 17 years): A single IV dose at 20 mcg/kg body weight. Which maximum dose is 1.5 mg.
Interaction
Contraindications
Side Effects
Pregnancy & Lactation
Overdose Effects
Storage Conditions
Alternative brands of Palonosetron
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.